Cardiol Therapeutics (CRDL) Receivables - Net (2020 - 2026)

Cardiol Therapeutics has reported Receivables - Net for 7 years, with the latest figure at $51099.8 in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 200.43% year-over-year to $51099.8; the trailing twelve-month figure through Mar 2026 stood at $51099.8 (up 200.43% YoY), and the FY2025 full-year result was $39961.1, down 44.38% from the prior year.
• Receivables - Net for Q1 2026 stood at $51099.8, up from $39961.1 in the prior quarter.
• The five-year high for Receivables - Net was $154650.9 in Q4 2022, with the low at -$67764.3 in Q3 2022.
• Historically, Receivables - Net has averaged $31445.5 across 5 years, with a median of $35894.6 in 2024.
• Annual changes were most pronounced in 2024 — Receivables - Net plunged 193.14% — and 2025, when it surged 304.09%.
• Cardiol Therapeutics' Receivables - Net stood at $154650.9 in 2022, then tumbled by 32.2% to $104851.3 in 2023, then slumped by 31.48% to $71846.9 in 2024, then tumbled by 44.38% to $39961.1 in 2025, then gained by 27.87% to $51099.8 in 2026.
• The last three Receivables - Net figures came in at $51099.8 (Q1 2026), $39961.1 (Q4 2025), and $45685.0 (Q3 2025), per Business Quant data.